These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28293470)

  • 1. Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial.
    Katz DA; Locke C; Greco N; Liu W; Tracy KA
    Brain Behav; 2017 Mar; 7(3):e00628. PubMed ID: 28293470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436.
    Katz DA; Liu W; Locke C; Dutta S; Tracy KA
    Psychopharmacology (Berl); 2016 Jan; 233(1):71-81. PubMed ID: 26407603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Dose Interaction Study of the Arginine Vasopressin Type 1B Receptor Antagonist ABT-436 and Alcohol in Moderate Alcohol Drinkers.
    Katz DA; Locke C; Liu W; Zhang J; Achari R; Wesnes KA; Tracy KA
    Alcohol Clin Exp Res; 2016 Apr; 40(4):838-45. PubMed ID: 26969417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin V1B Receptor Antagonists as Potential Antidepressants.
    Chaki S
    Int J Neuropsychopharmacol; 2021 Jul; 24(6):450-463. PubMed ID: 33733667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the naloxone test with ovine CRH and insulin hypoglycaemia in the evaluation of the hypothalamic-pituitary-adrenal axis in normal man.
    Inder WJ; Ellis MJ; Evans MJ; Donald RA
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):425-31. PubMed ID: 7586616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers.
    Sher L; Oquendo MA; Burke AK; Cooper TB; Mann JJ
    J Affect Disord; 2013 Dec; 151(3):1108-12. PubMed ID: 23866302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects.
    Rubin RT; O'Toole SM; Rhodes ME; Sekula LK; Czambel RK
    Psychiatry Res; 1999 Dec; 89(1):1-20. PubMed ID: 10643873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cortisol response patterns in depressed women and their healthy daughters at risk: Comparison with healthy women and their daughters.
    Gonul AS; Cetinkalp S; Tunay S; Polat I; Simsek F; Aksoy B; Kizilates G; Erdogan Y; Coburn KL
    J Psychiatr Res; 2017 Feb; 85():66-74. PubMed ID: 27837659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.
    Nikisch G; Mathé AA; Czernik A; Thiele J; Bohner J; Eap CB; Agren H; Baumann P
    Psychopharmacology (Berl); 2005 Oct; 181(4):751-60. PubMed ID: 15988572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a novel and selective V1B receptor antagonist.
    Craighead M; Milne R; Campbell-Wan L; Watson L; Presland J; Thomson FJ; Marston HM; Macsweeney CP
    Prog Brain Res; 2008; 170():527-35. PubMed ID: 18655906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study.
    Ventura-Juncá R; Symon A; López P; Fiedler JL; Rojas G; Heskia C; Lara P; Marín F; Guajardo V; Araya AV; Sasso J; Herrera L
    BMC Psychiatry; 2014 Aug; 14():220. PubMed ID: 25086452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Vasopressin on the Hypothalamic-Pituitary-Adrenal Axis in ADPKD Patients during V2 Receptor Antagonism.
    Heida JE; Minović I; van Faassen M; Kema IP; Boertien WE; Bakker SJL; van Beek AP; Gansevoort RT
    Am J Nephrol; 2020; 51(11):861-870. PubMed ID: 33147589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Vasopressin V1b Receptor Blockade on Activity of the Hypothalamic-Pituitary-Adrenal Axis in Old Monkeys with Depression-Like and Anxious Behavior Subjected to Stress or Injected with Vasopressin.
    Goncharova ND; Chigarova OA; Oganyan TE
    Bull Exp Biol Med; 2018 Nov; 166(1):86-91. PubMed ID: 30450521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Centrally administered murine-leptin stimulates the hypothalamus-pituitary- adrenal axis through arginine-vasopressin.
    Morimoto I; Yamamoto S; Kai K; Fujihira T; Morita E; Eto S
    Neuroendocrinology; 2000 Jun; 71(6):366-74. PubMed ID: 10878498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of Hatha yoga as an add-on treatment in major depression on hypothalamic-pituitary-adrenal-axis activity: a randomized trial.
    Sarubin N; Nothdurfter C; Schüle C; Lieb M; Uhr M; Born C; Zimmermannc R; Bühner M; Konopka K; Rupprecht R; Baghai TC
    J Psychiatr Res; 2014 Jun; 53():76-83. PubMed ID: 24655586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study.
    Vreeburg SA; Hoogendijk WJ; van Pelt J; Derijk RH; Verhagen JC; van Dyck R; Smit JH; Zitman FG; Penninx BW
    Arch Gen Psychiatry; 2009 Jun; 66(6):617-26. PubMed ID: 19487626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression.
    Scott LV; Dinan TG
    Life Sci; 1998; 62(22):1985-98. PubMed ID: 9627097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.
    Nothdurfter C; Schmotz C; Sarubin N; Baghai TC; Laenger A; Lieb M; Bondy B; Rupprecht R; Schüle C
    J Psychiatr Res; 2014 May; 52():15-20. PubMed ID: 24513501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.
    Schüle C; Baghai TC; Eser D; Zwanzger P; Jordan M; Buechs R; Rupprecht R
    Psychopharmacology (Berl); 2006 Jul; 186(4):601-11. PubMed ID: 16758243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.